EP2310020B1 - Novel acetates of 2-deoxy monosaccharides with anticancer activity - Google Patents

Novel acetates of 2-deoxy monosaccharides with anticancer activity Download PDF

Info

Publication number
EP2310020B1
EP2310020B1 EP09794965.5A EP09794965A EP2310020B1 EP 2310020 B1 EP2310020 B1 EP 2310020B1 EP 09794965 A EP09794965 A EP 09794965A EP 2310020 B1 EP2310020 B1 EP 2310020B1
Authority
EP
European Patent Office
Prior art keywords
glucose
ddd
mmol
cancer
autophagy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09794965.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2310020A4 (en
EP2310020A2 (en
Inventor
Waldemar Priebe
Marcin Cybulski
Izabela Fokt
Stainslaw Skora
Charles Conrad
Timothy Madden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to PL09794965T priority Critical patent/PL2310020T3/pl
Publication of EP2310020A2 publication Critical patent/EP2310020A2/en
Publication of EP2310020A4 publication Critical patent/EP2310020A4/en
Application granted granted Critical
Publication of EP2310020B1 publication Critical patent/EP2310020B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • glycolysis in cancer cells can be enhanced by certain oncogenes through the increased expression of glucose transporters and glycolytic enzymes found on tumor cells.
  • GBM glioblastoma multiforme
  • glioblastoma A serious disadvantage of treating glioblastoma is the harmful effects on normal cells and tissue. Mutagenic potential of certain neoplasmic therapies often promotes tumor resistance and can initiate other malignancies. Tumors can also develop resistance to various other treatments, such as anti-angiogenic therapy. A need exists, therefore, for cancer treatments for highly glycolytic cancer cells such as glioblastoma with little or no toxicity towards normal cells.
  • US 2004/167079 describes that the compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.
  • WO 01/82926 describes that a class of glycolytic inhibitors can be used in the treatment of solid tumors by attacking anaerobic cells at the center on the tumor. It is described that 2-deoxyglucose, oxamate and various analogs thereof are identified as having a natural selective toxicity toward anaerobic cells, and that they will significantly increase the efficacy of standard cancer chemotherapeutic and radiation regiments as well as new protocols emerging with anti-angiogenic agents.
  • Compounds for use in the treatment of tumors and tumor cell growth including primary tumors such as glioblastoma or high-grade gliomas, high-grade solid tumors, high-grade lymphomas, high-grade hematologic malignancies and secondary brain tumors such as metastatic brain tumors are presented herein.
  • primary tumors such as glioblastoma or high-grade gliomas, high-grade solid tumors, high-grade lymphomas, high-grade hematologic malignancies and secondary brain tumors such as metastatic brain tumors
  • Compounds for use in the treatment of cancer such as brain and pancreatic cancer, are described herein.
  • the invention provides a compound of the Formula I for use in the treatment of cancer as follows:
  • glioblastoma or high-grade gliomas
  • high-grade solid tumors high-grade lymphomas
  • high-grade hematologic malignancies and secondary brain tumors such as metastatic brain tumors are provided herein.
  • the invention provides a compound of Formulas I for use in the treatment of cancer as follows:
  • ATP adenosine 5'-triphosphate
  • pathways that generate energy in eukaryotic organisms include: (1) glycolysis; (2) the Krebs Cycle (also referred to as the TCA cycle or citric acid cycle); and (3) oxidative phosphorylation.
  • carbohydrates are first hydrolyzed into monosaccharides (e.g., glucose), and lipids are hydrolyzed into fatty acids and glycerol.
  • proteins are hydrolyzed into amino acids. The energy in the chemical bonds of these hydrolyzed molecules are then released and harnessed by the cell to form ATP molecules through numerous catabolic pathways.
  • glucose is a simple sugar or monosaccharide, and the primary source of energy for animals.
  • Glucose is an important sugar in human metabolism having a normal concentration of about 0.1% (usually 60 to 110 mgs per dl) in human blood except in persons suffering from diabetes.
  • glucose requires no digestion.
  • oxidation of glucose contributes to a series of complex biochemical reactions which provide the energy needed by cells.
  • glucose produces carbon dioxide, water and certain nitrogen compounds.
  • Energy from glucose oxidation is used to convert ADP to adenosine 5'-triphosphate ("ATP"), a multifunctional nucleotide that is known as "molecular currency” of intracellular energy transfer.
  • ATP adenosine 5'-triphosphate
  • ATP produced as an energy source during cellular respiration is consumed by different enzymes and cellular process including biosynthetic reactions, motility and cell division.
  • ATP is the substrate by which kinases phosphorylate proteins and lipids and adenylate cyclase produces cyclic AMP.
  • ATP is an unstable molecule that tends to be hydrolyzed in water. Thus, if ATP and ADP are allowed to come into chemical equilibrium, almost all the ATP will be converted to ADP. Cells maintain ATP to ADP at a point ten orders of magnitude from equilibrium, with ATP concentrations a thousand fold higher than the concentration of ADP. This displacement from equilibrium means that the hydrolysis of ATP in the cell releases a lot of energy. Nicholls D.G. & Ferguson S.J. (2002) Bioenergetics Academic Press 3rd Ed . ATP concentration inside the cell is typically 1-10 m M. Beis I., & Newsholme E.A. (1975) Biochem J 152, 23-32 .
  • ATP is produced by redox reactions using simple sugars (e.g., glucose), complex sugars (carbohydrates), lipids, and proteins.
  • carbohydrates are hydrolyzed into simple sugars such as glucose, or fats (triglycerides) are hydrolyzed to give fatty acids and glycerol.
  • proteins are hydrolyzed to give amino acids.
  • Cellular respiration is the process of oxidizing these hydrolyzed molecules to carbon dioxide to generate ATP. For instance, up to 36 molecules of ATP can be produced from a single molecule of glucose. Lodish, H. et al (2004) Molecular Cell Biology, 5th Ed. New York: WH Freeman .
  • the three main pathways to generate energy in eukaryotic organisms are: glycolysis, the Krebs Cycle (also known as the citric acid cycle), and oxidative phosphorylation.
  • the main source of energy for living organisms is glucose.
  • breaking down glucose the energy in the glucose molecule's chemical bonds is released and can be harnessed by the cell to form ATP molecules.
  • the process by which this occurs consists of several stages. The first is called glycolysis (the prefix glyco refers to glucose, and lysis means to split), in which the glucose molecule is broken down into two smaller molecules called pyruvic acid.
  • glycolysis the prefix glyco refers to glucose, and lysis means to split
  • the glucose molecule is broken down into two smaller molecules called pyruvic acid.
  • the next stages are different for anaerobes and aerobes.
  • glycolysis glucose and glycerol are metabolized to pyruvate via the glycolytic pathway. In most organisms, glycolysis occurs in the cytosol. During this process, two ATP molecules are generated. Two molecules of NADH are also produced, which can be further oxidized via the electron transport chain and result in the generation of additional ATP molecules.
  • Glycolysis is the first stage in the release of energy from the glucose molecule. It occurs in the cytoplasm via many enzymes. Both aerobic and anaerobic organisms use glycolysis to break down glucose to pyruvate initially. After this stage, however, aerobic organisms utilize oxygen to obtain additional energy.
  • Glycolysis involves the breaking down of glucose into two smaller molecules of pyruvic acid, each pyruvic acid molecule having three carbon atoms, or half of the carbons in a glucose molecule. Noteworthy, for glycolysis to occur, two ATP molecules are necessary. As shown in Figure 2 , the first ATP molecule releases a phosphate group which then joins to the glucose molecule to form glucose phosphate. Then, the second ATP molecule contributes a phosphate group, forming a molecule called fructose diphosphate.
  • the fructose diphosphate molecule splits into two molecules of glyceraldehyde phosphate "PGAL.” Each PGAL molecule then releases electrons to a coenzyme NAD+ (nicotinamide adenine dinucleotide) and phosphate groups and energy to ADP.
  • NAD+ nicotinamide adenine dinucleotide
  • pyruvic acid undergoes additional processing in order to obtain additional energy.
  • These processes are significantly less efficient than the processes which aerobes utilize: the Krebs cycle and the electron transport chain.
  • Glycolysis occurs in the cytoplasm and involves many enzyme-catalyzed steps that break down glucose (and other monosaccharides) into 2 pyruvate molecules. In return, the pathway leads to the generation of a sum of 2 ATP molecules.
  • the pyruvate molecules generated from the glycolytic pathway enter the mitochondria from the cytosol.
  • the molecules are then converted to acetyl co-enzyme A (Acetyl-CoA) for entry into the Krebs cycle.
  • the Krebs cycle consists of the bonding of acetyl coenzyme-A with oxaloacetate to form citrate.
  • the formed citrate is then broken down through a series of enzyme-catalyzed steps to generate additional ATP molecules.
  • the catabolic processes in glycolysis and the Krebs cycle also generate electrons that become stored in the form of reduced co-enzymes, such as NADH and FADH2.
  • These co-enzymes participate in oxidative phosphorylation, where their electrons pass through an electron transport chain across the mitochondrial membrane.
  • the protons from NADH and FADH2 enter the mitochondrial intermembrane space. Consequently, the electron transport chain leads to the formation of a proton gradient within the intermembrane space.
  • the protons flux from the intermembrane space to the mitochondrial matrix through specific proton channels that catalyze the synthesis of additional ATP molecules.
  • the tumor cells up-regulate the expression of both glucose transporters and glycolytic enzymes, in turn, favoring an increased uptake of glucose (as well as their analogs) as compared to normal cells in an aerobic environment.
  • This tumor adaptive response appears to hold true for malignant gliomas as well.
  • PI-3K/ AKT pathway typically by PTEN loss or through growth factor activity such as EGFR.
  • This survival pathway activates a number of adaptive changes that include a stimulus for angiogenesis, inhibition of apoptosis, and metabolic shifts that promote activation of glycolysis and an increase in glucose uptake.
  • the malignant phenotype that up-regulates the glycolysis pathways are also induced by c-Myc, Hif-1 ⁇ , and STAT-3, all of which have been implicated in high-grade malignant transformation.
  • malignant transformations display a differential growth pattern.
  • Namelv. malignant tumors can grow in predominately hypoxic and mixed regions of variable degrees of normoxia. Relative hypoxic areas can be seen both in the center of the rapidly growing tumor mass, which often has regions of necrosis associated with this, as well as some relatively hypoxic regions within infiltrative components of the tumor as well. Accordingly, some of these relatively hypoxic regions may have cells that are cycling at a slower rate and may therefore be more resistant to many chemotherapy agents. For instance, gliomas can grow in a predominately infiltrative fashion with little to no contrast enhancement seen on MRI scans versus more rapidly growing contrast enhancing mass lesions.
  • VEGF vascular endothelial growth factor
  • malignant gliomas and pancreatic cancer are intrinsically resistant to conventional therapies and represent significant therapeutic challenges.
  • Malignant gliomas have an annual incidence of 6.4 cases per 100,000 (Central Brain Tumor Registry of the United States, 2002-2003 ) and are the most common subtype of primary brain tumors and the deadliest human cancers.
  • GBM glioblastoma multiforme
  • the median survival duration for patients ranges from 12 to 14 months, despite maximum treatment efforts.
  • approximately one-third of patients with GBM their tumors will continue to grow despite treatment with radiation and chemotherapy.
  • the prognosis for pancreatic cancer is generally regarded as poor, with few victims still alive 5 years after diagnosis, and complete remission rare.
  • Another problem in treating malignant tumors is the toxicity of the treatment to normal tissues unaffected by disease. Often chemotherapy is targeted at killing rapidly-dividing cells regardless of whether those cells are normal or malignant. However, widespread cell death and the associated side effects of cancer treatments may not be necessary for tumor suppression if the growth control pathways of tumors can be disabled.
  • therapy sensitization i.e. using low dose of a standard treatment in combination with a drug that specifically targets crucial processes in the tumor cell, increasing the effects of the other drug.
  • the glycolytic pathway has become a potential target for the selective inhibition of many tumor cells, particularly glioblastomas and pancreatic cancers and other highly glycolytically sustained tumors.
  • the inhibition of glycolysis would be selective for such tumor cells because normal cells in aerobic conditions would be able to survive such inhibition by generating energy through other pathways (e.g., the Krebs cycle, and oxidative phosphorylation).
  • the Krebs cycle e.g., the Krebs cycle, and oxidative phosphorylation
  • glycolytic inhibition approaches for cancer treatment present various challenges. For instance, many such treatments are not specific for the hypoxic environment of tumor cells. More importantly, current treatments are not selective inhibitors of glycolysis. Rather, such treatments can also target other pathways that are essential for normal cell function, such as glycosylation, where monosaccharides such as D-mannose are linked to proteins to form glycoproteins. Among other functions, glycoproteins are essential for maintaining the structural integrity of cell membrane
  • combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • glycolysis inhibitor As used herein, references to “glycolysis inhibitor,” “glycolytic inhibitor” or “inhibitor(s) of glycolysis” are intended to refer to compounds or compositions that substantially inhibit or interfere with the activity of one or more enzymes involved in glycolysis.
  • inhibiting glycolysis is intended to refer to a decrease in glycolytic activity, a reduction in glycolytic activity, or the elimination of glycolytic activity.
  • IC 50 is intended to refer to the concentration of a compound or composition that reduces the viability of cells to half the original level. In broader terms, IC 50 can refer to half the maximal inhibitory concentration of a substance for inhibiting various biological processes.
  • terapéuticaally effective is intended to qualify the amount of active ingredients that is used in the treatment of a disease or disorder described in the present disclosure. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
  • treatment of a patient is intended to refer to procedures or applications of the compounds of the present invention to a patient in order to temporarily or permanently cure, reduce, mitigate, or ameliorate a condition or disorder described in the present disclosure.
  • patient is intended to refer to all mammals including but not limited to humans, cows, dogs, cats, goats, sheep, pigs, and rabbits.
  • the patient is a human.
  • hypooxic is intended to refer to a condition characterized by low oxygen supply.
  • normoxic is intended to refer to a condition characterized by adequate oxygen supply.
  • Autophagy is a regulated process in which portions of the cytoplasm are first sequestered with double-membrane vesicles known as autophagosomes. Klionsky, D.J., et al., Autophagy as a Regulated Pathway of Cellular Degradation, Science, 2000, 290:1717-1721 . These autophagosomes then fuse with lysosomes to become autolysosomes or degradative autophagic vacuoles, after which the sequestered contents are degraded by lysosomal hydrolases. Autophagy leads to the extensive degradation of organelles, including mitochondria, which precedes nuclear destruction.
  • Autophagy is induced in various cell conditions; for example, it is responsible for the degradation of normal proteins in response to nutrient deprivation, differentiation, aging, transformation, and cancer. Cuervo, A.M., Autophagy: In Sickness and in Health, Trends Cell Biol, 2004, 14: 70-77 ; Shintani, T., et al., Autophagy in Health and Disease: A Double-Edged Sword, Science, 2004, 306: 990-995 . In cancer research, autophagy is a novel concept, and its role remains unclear. In general, cancer cells show less autophagic degradation than normal cells. Bursch, W., et al., Programmed Cell Death (PCD). Apoptosis, Autophagic PCD, or Others? Ann.
  • PCD Programmed Cell Death
  • the compounds presented herein for use in the treatment of cancer may be administered in combination with one or more compounds and/or other agents including anti-cancer agents, anti-angiogenic agents and/or autophagy inducing agents.
  • Anti-cancer agents that are suitable for use with the compounds described herein include: antitumor antibiotics (anthracyclines, mitoxantrone, bleomycin, mithramycin); Fludarabine, Gemcetobine, temozolamide (Temodar); cyclophosphamides; fluoropyrimidines (such as capecitabine); fluorouracil (5-FU or Adrucil); nitrosoureas, such as procarbazine (Matulane), lomustine, CCNU (CeeBU), 3-[(4-amino-2-methyl-pyrimidin-5-yl)methyl]-1-(2-chloroethyl)-1-nitroso-urea carmustine (ACNU), (BCNU, BiCNU, Gliadel Wafer), and estramustine (Emcyt); nitrogen mustard; melphalan; chlorambucil; busulphan; ifosfamide nitrosoureas; thiot
  • Temodar and other suitable anti-cancer agents may be administered at therapeutically effective dosages under different schedules, as envisioned by people of ordinary skill in the art.
  • the anti-cancer agents can be administered at 100 mg per m 2 body weight for seven consecutive days on a bi-weekly basis.
  • the anti-cancer agents may also be administered at the same dosage for 21 days on and 7 days off.
  • Other therapeutic dosages and administration schedules can also be envisioned by people of ordinary skill in the art.
  • VEGF inhibitors e.g., Avastin
  • VEGF Trap VEGF Trap
  • Sorafinib VEGF Trap
  • Sutin VEGF Trap
  • Sorafinib VEGF Trap
  • Sutin VEGF Trap
  • anti-angiogenic agents may be small molecules, anti-bodies, aptamers, proteins, polypeptides, and other compounds or compositions that reduce or eliminate angiogenic activity.
  • Anti-angiogenic agents may be administered at a therapeutically effective dose under different schedules.
  • Avastin may be administered to a patient at a dose of 5, 10 or 15 mg per kg body weight once every two or three weeks. Alternatively, 3-20 mg/kg once every 2-3 weeks is suitable.
  • One or more autophagy-inducing agents may also be suitable for use with the compounds presented herein.
  • Rapamycin is useful as an autophagy-inducing agent.
  • Other autophagy-inducing agents include concanavalin A, inhibitors of eEF-2 Kinase Inhibitors and histone deactylase inhibitors like SAHA.
  • Autophagy is a regulated process in which portions of the cytoplasm are first sequestered with double-membrane vesicles known as autophagosomes. Klionsky, D.J., et al., Autophagy as a Regulated Pathway of Cellular Degradation, Science, 2000, 290:1717-1721 . These autophagosomes then fuse with lysosomes to become autolysosomes or degradative autophagic vacuoles, after which the sequestered contents are degraded by lysosomal hydrolases. Autophagy leads to the extensive degradation of organelles, including mitochondria, which precedes nuclear destruction.
  • Autophagy is induced in various cell conditions; for example, it is responsible for the degradation of normal proteins in response to nutrient deprivation, differentiation, aging, transformation, and cancer. Cuervo, A.M., Autophagy: In Sickness and in Health, Trends Cell Biol, 2004, 14: 70-77 ; Shintani, T., et al., Autophagy in Health and Disease: A Double-Edged Sword, Science, 2004, 306: 990-995 . In cancer research, autophagy is a novel concept, and its role remains unclear. In general, cancer cells show less autophagic degradation than normal cells. Bursch, W., et al., Programmed Cell Death (PCD). Apoptosis, Autophagic PCD, or Others? Ann.
  • PCD Programmed Cell Death
  • the combination therapies are particularly suitable for use in treating brain tumors including primary tumors such as glioblastoma or high-grade gliomas, and secondary brain tumors such as metastatic brain tumors.
  • primary tumors such as glioblastoma or high-grade gliomas
  • secondary brain tumors such as metastatic brain tumors.
  • One unique property of the CNS is its striking predilection to uptake glucose and its analogs.
  • Hypoglycemic agents suitable for use with the present invention include compounds that reduce blood glucose levels.
  • Non-limiting examples of such compounds include insulin, alpha-glucosidase inhibitors, sulfonylureas, meglitinides, D-phenyl alanine derivatives, biguanides, thiazolidinediones, GLP-1 analogues, and DPP-4 inhibitors.
  • the preferred route of administration can vary depending on the compounds being used and such routes include, but are not limited to, oral, buccal, intramuscular (Lm.), intravenous (i.v.), intraparenteral (i.p.), topical, or any other FDA recognized route of administration.
  • the administered or therapeutic concentrations will also vary depending upon the patient being treated and the compounds being administered.
  • a pharmaceutical formulation can comprise the compound together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g. , in Remington's Pharmaceutical Sciences.
  • the pharmaceutical compositions may be manufactured in a manner that is itself known, e.g. , by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the compound ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • the compounds may also be formulated for parenteral administration by injection, e.g. , by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g. , in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
  • sterile liquid carrier for example, saline or sterile pyrogen-free water
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of DFGs to allow for the preparation of highly concentrated solutions.
  • formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • the amount of the compound that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity.
  • the compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, and rodents.
  • More preferred animals include horses, dogs, and cats.
  • the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • the benefit of experienced by a patient may be increased by administering one of compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • increased therapeutic benefit may result by also providing the patient with another therapeutic agent for diabetes.
  • the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
  • the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
  • 6-O-acyl-4-O-benzyl-2-deoxy-D-glucose 6-O-Acetyl-4-O-benzyl-D-glucal (2.5 mmol) was dissolved in THF (50 mL). 48% Water solution of hydrobromic acid (0.5 mL) was added and the reaction mixture was stirred at room temperature. After 1 hr, reaction was completed, water (250 mL) was added, then pH of obtained solution was adjusted to 8 using saturated sodium carbonate. Water solution was then extracted with ethyl acetate (3 x 100 mL). Combined water extracts were washed with water until neutral, and dried over anhydrous sodium sulfate. Solids and solvents were removed and crude product was purified by column chromatography (SilicaGel 60) using hexanes:ethyl acetate as eluents. (Yield 48%).
  • Additional novel compounds for use in the treatment described herein include:
  • the compound of Example 4 performed even better. This compound provided mean plasma concentrations more than 6-fold > that observed with equivalent doses of 2-DG. Likewise peak brain tissue concentrations were also consistently greater (387.1 vs. 13.7 ⁇ g/gm) than for equivalent doses of 2-DG.
  • This compound of Example 4 derived 2-DG exposure was of longer duration in the CNS as well, with 2-DG measurable in brain tissue for 8 times longer following the administration of this compound than with comparable 2-DG administration. In fact, at 2 hrs after 2-DG administration the highest attained brain tissue concentration was 12 ⁇ g/gm, while 4 hours after dosing with the compound of Example 4, 2-DG concentrations of 256 ⁇ g/gm of brain tissue were observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP09794965.5A 2008-07-11 2009-06-25 Novel acetates of 2-deoxy monosaccharides with anticancer activity Active EP2310020B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL09794965T PL2310020T3 (pl) 2008-07-11 2009-06-25 Nowe octany 2-deoksymonosacharydów o aktywności przeciwnowotworowej

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7996808P 2008-07-11 2008-07-11
PCT/US2009/048675 WO2010005799A2 (en) 2008-07-11 2009-06-25 Novel acetates of 2-deoxy monosaccharides with anticancer activity

Publications (3)

Publication Number Publication Date
EP2310020A2 EP2310020A2 (en) 2011-04-20
EP2310020A4 EP2310020A4 (en) 2012-04-25
EP2310020B1 true EP2310020B1 (en) 2017-03-15

Family

ID=41507670

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09794965.5A Active EP2310020B1 (en) 2008-07-11 2009-06-25 Novel acetates of 2-deoxy monosaccharides with anticancer activity

Country Status (10)

Country Link
US (1) US8927506B2 (enExample)
EP (1) EP2310020B1 (enExample)
JP (2) JP5677951B2 (enExample)
CN (1) CN102149388B (enExample)
DK (1) DK2310020T3 (enExample)
ES (1) ES2628180T3 (enExample)
HU (1) HUE033210T2 (enExample)
LT (1) LT2310020T (enExample)
PL (1) PL2310020T3 (enExample)
WO (1) WO2010005799A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
JP5677951B2 (ja) 2008-07-11 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌活性を有する２−デオキシ単糖の新規なアセテート
JP2014505058A (ja) * 2011-01-11 2014-02-27 ザ・ユニバーシティ・オブ・テキサス・エム・ディー・アンダーソン・キャンサー 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
WO2012142615A2 (en) * 2011-04-14 2012-10-18 Board Of Regents, The University Of Texas System Auranofin and auranofin analogs useful to treat proliferative disease and disorders
KR20150002781A (ko) * 2012-04-12 2015-01-07 고꾸리츠 다이가꾸호오징 기후다이가꾸 경색 치료용 의약 조성물
PL2981270T3 (pl) 2013-04-05 2022-05-09 Board Of Regents, The University Of Texas System Estry 2-deoksy-monosacharydów o działaniu przeciwproliferacyjnym
WO2020035782A1 (en) * 2018-08-13 2020-02-20 Dermin Sp. Z O.O. Molecular probes for analysis of metabolism of glycolysis inhibitors prodrugs and synthesis methods therefore
CA3170872A1 (en) 2020-03-16 2021-09-23 Board Of Regents, The University Of Texas System Method of treating viral infections with hexose type monosaccharides and analogs thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56103197A (en) * 1980-01-21 1981-08-18 Wakamoto Pharmaceut Co Ltd Novel d-glucose derivative and antitumor agent containing the same as active constitutent
JPS58167582A (ja) 1982-03-29 1983-10-03 Takeda Chem Ind Ltd 糖ケタ−ルの製造法
US6319695B1 (en) 1991-10-15 2001-11-20 The Scripps Research Insitute Production of fucosylated carbohydrates by enzymatic fucosylation synthesis of sugar nucleotides; and in situ regeneration of GDP-fucose
EP0851866B1 (en) * 1995-06-23 2001-08-29 Oxford GlycoSciences (UK) Limited Therapeutic compounds
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
CN1541106A (zh) 2001-06-11 2004-10-27 转新疗法公司 用维生素b12和治疗剂联合治疗病毒性、增殖性和炎性疾病的方法
WO2003018598A2 (en) 2001-08-30 2003-03-06 University College Dublin Monosaccharide derivatives
WO2003082301A1 (en) 2002-03-29 2003-10-09 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
EP1587519A4 (en) * 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc Treatment of cancer with 2-deoxyglucose
CA2431425A1 (en) 2003-06-05 2004-12-05 Angiogene, Inc. Epas1 gene transfer to improve cell therapy
WO2005065721A2 (en) 2003-12-30 2005-07-21 Board Of Regents, The University Of Texas System Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex
US20070292478A1 (en) 2004-08-30 2007-12-20 Popowski Youri Medical Implant Provided with Inhibitors of Atp Synthesis
MX2008010833A (es) 2006-02-24 2008-11-12 Univ Texas Compuestos de hexosa para tratar cancer.
WO2007100728A2 (en) 2006-02-24 2007-09-07 University Of Miami Mannose derivatives for killing tumor cells
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
EP1881000A1 (en) * 2006-07-17 2008-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Conjugates of 2-fluoro-2-deoxy-glucose and their uses as anti cancer agents
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
JP5677951B2 (ja) 2008-07-11 2015-02-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗癌活性を有する２−デオキシ単糖の新規なアセテート
WO2012142615A2 (en) 2011-04-14 2012-10-18 Board Of Regents, The University Of Texas System Auranofin and auranofin analogs useful to treat proliferative disease and disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2010005799A2 (en) 2010-01-14
WO2010005799A3 (en) 2010-04-29
DK2310020T3 (en) 2017-06-26
EP2310020A4 (en) 2012-04-25
CN102149388A (zh) 2011-08-10
JP5677951B2 (ja) 2015-02-25
JP2015091849A (ja) 2015-05-14
EP2310020A2 (en) 2011-04-20
PL2310020T3 (pl) 2017-10-31
HUE033210T2 (hu) 2017-11-28
JP5890043B2 (ja) 2016-03-22
CN102149388B (zh) 2014-11-05
LT2310020T (lt) 2017-07-25
US20110160151A1 (en) 2011-06-30
ES2628180T3 (es) 2017-08-02
JP2011527678A (ja) 2011-11-04
US8927506B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
EP2310020B1 (en) Novel acetates of 2-deoxy monosaccharides with anticancer activity
RU2488591C2 (ru) Аналоги азацитидина и их применение
US8299033B2 (en) Iodo-hexose compounds useful to treat cancer
US20100222285A1 (en) Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation
US20120276108A1 (en) Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
JPH02111724A (ja) アデニンヌクレオチドを有効成分とする血液および血漿中のアデノシン５’‐トリホスフェートレベルを増加させる薬剤
EP2583972B1 (en) Therapeutic agent for inflammatory diseases containing adenosine n1-oxide as active ingredient
US9149489B2 (en) Inhibitors of glycolysis useful in the treatment of brain tumors
JP2009531301A (ja) 癌治療のためのヘキソース化合物
JPH06501483A (ja) 寄生性原虫によって起こる疾患および新形成性疾患の治療用薬剤
CN106413753A (zh) 用于治疗用途的糖脂及其药物组合物
WO1999013739A1 (en) Fatty acids as a diet supplement
WO2009143078A2 (en) Methods of treating brain cancer using hexose compounds
EP2636677B1 (en) Cdk-inhibiting pyrrolopyrimidinone carboxamide derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating liver cell cancer
EP3974437B1 (en) D-glucopyranoside and salts thereof
WO1998027977A1 (en) Delivering therapeutically effective amounts of pyruvate
WO2022006673A1 (en) Anti-cancer activity of perborate salts
CN107921134B (zh) 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物
TW202539625A (zh) 包括９－順式視黃酸及單醣之綴合化合物
JP2016020339A (ja) １，４−ジヒドロキシ−２−ナフトエ酸誘導体
FR2530142A1 (fr) Composition contenant un agent renforcant les effets antitumoraux, et medicament comprenant une substance antitumorale et un tel agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120322

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7012 20060101ALI20120316BHEP

Ipc: A61K 31/70 20060101AFI20120316BHEP

Ipc: A61P 35/00 20060101ALI20120316BHEP

17Q First examination report despatched

Effective date: 20150304

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20161121BHEP

Ipc: A61K 31/7024 20060101ALI20161121BHEP

Ipc: A61K 31/70 20060101AFI20161121BHEP

Ipc: C07H 5/02 20060101ALI20161121BHEP

Ipc: A61K 31/7012 20060101ALI20161121BHEP

INTG Intention to grant announced

Effective date: 20161205

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 874860

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009044810

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170623

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170616

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170615

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2628180

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170802

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E013867

Country of ref document: EE

Effective date: 20170606

Ref country code: AT

Ref legal event code: MK05

Ref document number: 874860

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170615

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 24471

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033210

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170717

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009044810

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

26N No opposition filed

Effective date: 20171218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170630

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170625

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170315

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230616

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240627

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240627

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20240603

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240627

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240625

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240626

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240606

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20240531

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240605

Year of fee payment: 16

Ref country code: FR

Payment date: 20240625

Year of fee payment: 16

Ref country code: EE

Payment date: 20240603

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240603

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20240605

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240619

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240704

Year of fee payment: 16

Ref country code: ES

Payment date: 20240701

Year of fee payment: 16